One of my favourite FTSE 100 stocks is down 42%. But it’s now making a rapid recovery

This FTSE 100 stock was absolutely crushed in the pandemic. But it now appears to be in the early stages of an uptrend.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Medical technology company Smith & Nephew‘s (LSE: SN.) one of my favourite FTSE 100 stocks. Currently, it’s the fourth largest individual Footsie holding in my entire investment portfolio.

This stock was hammered during the coronavirus pandemic and it’s still down 42% from its highs. But the good news is that it now appears to be making a fast recovery.

A new uptrend

In late October 2023, Smith & Nephew’s share price hit a 10-year low of 887p. I’m convinced that that was the bottom for the healthcare stock.

Should you invest £1,000 in HSBC right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if HSBC made the list?

See the 6 stocks

Since then, the share price has been quietly starting a new uptrend. Currently, the stock’s above both its 50-day and 200-day moving averages (these are technical indicators that can be used to identify share price trends). And recently, it experienced a ‘golden cross’ – a pattern that indicates a stock’s turned a corner into a bullish phase.

Created with Highcharts 11.4.3Smith & Nephew Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Improving performance

It’s not hard to see why the stock’s rising again. Recently, results have shown the company – which specialises in joint replacement technology – is recovering from Covid disruption, and that its transformation plan (announced in 2022) is working.

For example, half-year results posted in early August showed a 5.6% increase in revenue. Meanwhile, trading profit came in at $471m, up 12.8% year on year and ahead of analysts’ forecast.

Encouragingly, CEO Deepak Nath said that there’s scope for further progress: “There is still more work to be done and we expect to see further progress in the second half of the year.”

Still cheap

Looking at today’s valuation, I see plenty of room for further share price gains. Currently, analysts expect Smith & Nephew to generate earnings per share of 110 cents next year. So at today’s share price, the forward-looking price-to-earnings (P/E ratio) here is about 13.9.

That’s relatively low for a high-quality healthcare business. If the company was able to show that it’s firing on all cylinders, I wouldn’t be surprised to see the P/E ratio rise to somewhere between 18 and 20 (meaning the shares could potentially rise up to 44% from here).

It’s worth noting that back in July, activist investor Cevian Capital disclosed a 5% stake in the company. So it clearly sees value in the stock.

At the time, the firm – which is known for taking stakes in businesses and calling for change – said it saw the potential to create ”significant long-term value” by improving the operating performance of the medical technology company.

I’m bullish

Now, there’s no guarantee the shares will keep rising from here, of course. This company operates in a competitive industry, and it’s up against some formidable rivals.

Another risk is GLP-1 weight-loss drugs. These could have an impact on the dynamics of the joint replacement industry (less body weight, less pressure on joints).

All things considered however, I’m bullish on this stock. With the world’s ageing population likely to boost the joint replacement market in the years ahead, I see a lot of investment appeal.

Should you buy HSBC now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Pound coins for sale — 51 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »